We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+29.5%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$275M
AUM Growth
–
Cap. Flow
+$252M
Cap. Flow
% of AUM
91.48%
Top 10 Holdings %
Top 10 Hldgs %
61.92%
Holding
65
New
65
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$24M |
| 2 |
Baxter International
BAX
|
+$23.7M |
| 3 |
Medtronic
MDT
|
+$22.5M |
| 4 |
AbbVie
ABBV
|
+$18.6M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
+$17.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.78% |
| 2 | Consumer Staples | 1.61% |
| 3 | Communication Services | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Curis
CRIS
$8.85M
| $2.95M | 1.07% |
+902
| New | +$1.08M |
|
27
Cardiff Oncology
CRDF
$74.3M
| $2.83M | 1.03% |
+157,403
| New | +$2.77M |
|
28
Syndax Pharmaceuticals
SNDX
$1.77B
| $2.64M | 0.96% |
+118,833
| New | +$2.46M |
|
|
MREO
29
Mereo BioPharma
MREO
$48.4M
| $2.61M | 0.95% |
+728,710
| New | +$1.83M |
|
|
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.7M | 0.62% |
+19,832
| New | +$1.68M |
|
|
ONCT
31
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $1.4M | 0.51% |
+14,286
| New | +$904K |
|
32
Cellectar Biosciences
CLRB
$20.1M
| $1.37M | 0.5% |
+2,195
| New | +$1.01M |
|
|
NMTR
33
DELISTED
9 Meters Biopharma
NMTR
| $1.2M | 0.43% |
+69,541
| New | +$1.16M |
|
34
Arcturus Therapeutics
ARCT
$178M
| $1.16M | 0.42% |
+26,722
| New | +$1.81M |
|
|
MYOV
35
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.13M | 0.41% |
+40,910
| New | +$796K |
|
36
Protara Therapeutics
TARA
$225M
| $950K | 0.35% |
+39,225
| New | +$846K |
|
37
Theravance Biopharma
TBPH
$876M
| $877K | 0.32% |
+49,373
| New | +$886K |
|
38
Neurocrine Biosciences
NBIX
$16.4B
| $688K | 0.25% |
+7,178
| New | +$693K |
|
39
Procter & Gamble
PG
$342B
| $447K | 0.16% |
+3,210
| New | +$449K |
|
40
BioXcel Therapeutics
BTAI
$26M
| $445K | 0.16% |
+602
| New | +$469K |
|
41
Mondelez International
MDLZ
$79.9B
| $386K | 0.14% |
+6,608
| New | +$378K |
|
42
Colgate-Palmolive
CL
$74.4B
| $371K | 0.13% |
+4,343
| New | +$359K |
|
|
CBAY
43
DELISTED
Cymabay Therapeutics
CBAY
| $356K | 0.13% |
+62,000
| New | +$469K |
|
44
Black Diamond Therapeutics
BDTX
$103M
| $330K | 0.12% |
+10,283
| New | +$338K |
|
45
Verizon
VZ
$193B
| $319K | 0.12% |
+5,437
| New | +$323K |
|
46
Costco
COST
$418B
| $317K | 0.12% |
+841
| New | +$314K |
|
47
Kimberly-Clark
KMB
$37.3B
| $309K | 0.11% |
+2,291
| New | +$321K |
|
48
Merck
MRK
$317B
| $297K | 0.11% |
+3,805
| New | +$291K |
|
49
Penumbra
PEN
$12.7B
| $297K | 0.11% |
+1,695
| New | +$371K |
|
50
Hormel Foods
HRL
$13.9B
| $287K | 0.1% |
+6,148
| New | +$300K |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Tri Locum Partners, which disclosed 65 positions worth $275M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is Johnson & Johnson: 162,633 shares worth $25.6M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Consumer Staples and Communication Services.
- Tri Locum Partners's largest Q4 2020 buy was Johnson & Johnson: 162,633 shares worth $25.6M.
- Tri Locum Partners's ten largest holdings make up 62% of its $275M portfolio in Q4 2020.
- Tri Locum Partners disclosed 65 positions in Q4 2020, its first 13F filing on record.
Based on Tri Locum Partners's 13F filing for Q4 2020, filed 16 Feb 2021.